millipore 90mm滤膜0.22um亲水性PVDF过滤膜GVWP09050

说明: Durapore 表面滤膜，PVDF，亲水，0.22 µm，90 mm，白色，光面

商标名: Durapore

数量/包装: 50

应用: 除菌过滤生物溶液

滤膜材质: Hydrophilic PVDF

滤膜商标名: Durapore®

折射率: 1.42

水通量，mL/min x cm²: 6.7

23 °C 时的泡点: ≥3.45

zui高操作温度，°C: 85

滤膜类型: 表面滤膜

滤膜孔径，µm: 0.22

可润湿性: 亲水

滤膜直径，mm: 90

滤膜代码: GVWP

滤膜颜色: 白色

产品名称: Durapore 表面滤膜

滤膜表面: 光面

重量分析溶出物，%: 0.5

空气流速，L/min x cm²: 2

孔隙率 %: 70

技术指标

颜色：白色
表面：光面
厚度：125 µm
灭菌方法：高温高压灭菌（121 °C，1 bar）、EO 或 γ 射线
操作温度：85 °C
细菌内毒素：0.5 EU/mL
重量溶出物：< 0.5%

S-Pak网格滤膜0.22um微生物检测滤膜（无菌单独包装）GSWG047S6

说明: S-Pak 滤膜，0.22µm 47mm 白色网格

商标名: S-Pak

数量/包装: 600

应用: 微生物分析

滤膜材质: Mixed Cellulose Esters

滤膜孔径，µm: 0.22

包装: S-Pak 滤膜，单独密封，带蓝色隔膜纸，无菌

滤膜直径，mm: 47

滤膜颜色: 白色

产品名称: S-Pak 无菌滤膜

滤膜表面: 网格

无菌: 无菌

S-Pak 网格滤膜，无菌独立包装，使用混合纤维素酯制成，经优化，适合对水或其它液体进行 MF 方法微生物分析。

类型 HA （0.45 µm） 适合整体大肠菌群或酵母菌和霉菌分析；类型 HC （0.7 µm） 适合粪大肠菌群分析，其中膜的漏斗型的孔增强了受压有机体回收率；类型 RA （1.2 µm） 适合酵母菌和霉菌分析，用于难以过滤的液体。

HAWG/HCWG 类型膜的质量证书证实符合标准的方法。

WHATMAN 934-AH玻璃纤维滤纸1827-125，1.5um玻璃纤维滤纸现货供应

Grade 934-AH：1.5µm

这是一种改良的玻璃微纤维滤纸，无粘结剂，表面光滑，在更快的流速和高负载下，具有极好的颗粒物截留度，934-AH是*水质检测站每天测定总悬浮固体和总溶解性固体的标准过滤膜，它还可去除浑浊物和过滤培养基。zui近又称为国家标准方法中huang qu mei du su、赭曲霉毒素等样品过滤分离玻璃微纤维滤纸（1.5um 直径11cm），还可用于液闪计数、细胞培养和空气污染监测。

WHATMAN 934-AH玻璃纤维滤纸1827-125，1.5um玻璃纤维滤纸现货供应订购信息：

技术参数：

支原体预防试剂现货促销Invivogen Plasmocin™ prophylactic

Plasmocin™

Mycoplasma Removal Agent

Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. 
Plasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.
More info on Mycoplasma eradication

Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. 
The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.

Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.

• Specifications
• Docs
• Contents
• Description
• Details
• Citations

– Active on both free mycoplasmas and intracellular forms
– No resistance in liquid cultures of mycoplasmas
– No apparent adverse effect on cellular metabolism
– Active at low concentrations on a broad range of Gram positive and negative bacteria
– Eliminates mycoplasma in as little as 2 weeks
– Treat up to 25 cell lines in T75

• TDS Plasmocin™ prophylactic : 25 mg （10 x 1 ml） （ant-mpp）
• TDS Plasmocin™ treatment : 50 mg （2 x 1 ml） （ant-mpt）
• MSDS Plasmocin™ prophylactic : 25 mg （10 x 1 ml） （ant-mpp） , 50 mg （2 x 1 ml） （ant-mpt）

Plasmocin™ is provided as a yellow solution at different concentrations:

–  25 mg/ml （Plasmocin™Treatment）

–  2.5 mg/ml （Plasmocin™ Prophylactic）

In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.

In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.

No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.

Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.

Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.

Comparison of the most common anti-mycoplasma agents [1-3]

Antibiotics commonly used in cell culture are inactive on mycoplasma （e.g. penicillins and streptomycin）. Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin （Roche） contains a macrolide and a tetracycline, Ciprobay （Bayer, available only with a prescription） and MRA （ICN） are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].

1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A（11-12）:708-10
3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A（5）:344-7

Recent articles using Plasmocin™

• 2012 – J Virol Methods., Epub ahead of print
  Mycoplasma removal: Simple curative methods for viral supernatants.
  Baronti C, Pastorino B, Charrel R, de Lamballerie X
• 2011 – Mol Pharmacol., 80（6）:1066-75
  Ca2+/calmodulin-dependent kinase （CaMK） signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy.
  Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
• 2011 – J Immunol., 186（12）:6822-6829
  Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
  Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
• 2012 – J. Biol. Chem., 287: 8082 – 8091
  Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 （TRPML1） leads to cathepsin B-dependent apoptosis.
  Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
• 2012 – Immunity, 36（3）:464-476
  An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
  Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C

ORDERING

Plasmocin™ prophylactic

• TDS
• MSDS

Plasmocin™ treatment

• TDS
• MSDS

YOU MAY ALSO NEED

进口支原体清除剂现货促销Invivogen Plasmocin™ treatmen

Plasmocin™

Mycoplasma Removal Agent

Plasmocin™ is used to cure cell lines infected by mycoplasma and related cell wall-less bacteria. 
Plasmocin™ can also be used as a routine addition in liquid media to prevent mycoplasma and more generally bacterial contamination in small and large animal cell cultures.
More info on Mycoplasma eradication

Plasmocin™ is a well-established antimycoplasma reagent. It contains two bactericidal components strongly active against mycoplasmas that allow their elimination in only 2 weeks. 
The first component acts on the protein synthesis machinery while the second acts on the DNA replication. These two specific and separate targets are found only in mycoplasmas and many other bacteria and are compley absent in eukaryotic cells.

Warning: InvivoGen's anti-mycoplasma products are suitable for research purposes only, and not for human or animal care.

• Specifications
• Docs
• Contents
• Description
• Details
• Citations

– Active on both free mycoplasmas and intracellular forms
– No resistance in liquid cultures of mycoplasmas
– No apparent adverse effect on cellular metabolism
– Active at low concentrations on a broad range of Gram positive and negative bacteria
– Eliminates mycoplasma in as little as 2 weeks
– Treat up to 25 cell lines in T75

• TDS Plasmocin™ prophylactic : 25 mg （10 x 1 ml） （ant-mpp）
• TDS Plasmocin™ treatment : 50 mg （2 x 1 ml） （ant-mpt）
• MSDS Plasmocin™ prophylactic : 25 mg （10 x 1 ml） （ant-mpp） , 50 mg （2 x 1 ml） （ant-mpt）

Plasmocin™ is provided as a yellow solution at different concentrations:

–  25 mg/ml （Plasmocin™Treatment）

–  2.5 mg/ml （Plasmocin™ Prophylactic）

In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasmas and intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasmas released from intracellular compartments of infected cells.

In all animal cell lines tested to date, even at five times the working concentration, no apparent adverse effect on cellular metabolism is observed.

No resistance in liquid cultures of mycoplasmas has ever been identified in repeated experiments attempting to measure the mutation rate. Therefore, development of resistant mycoplasma strains is virtually eliminated.

Plasmocin™ is also active at low concentrations on a broad range of Gram positive and Gram negative bacteria that are otherwise resistant to the mixture of streptomycin and penicillin, and exhibits no toxicity in eukaryotic cells.

Many cell lines infected by mycoplasmas have been successfully treated with Plasmocin™, including embryonic stem cells, hybridomas and retrovirus packaging cells.

Comparison of the most common anti-mycoplasma agents [1-3]

Antibiotics commonly used in cell culture are inactive on mycoplasma （e.g. penicillins and streptomycin）. Three classes of antibiotics have been shown to kill mycoplasma at relatively low concentrations: tetracyclines, macrolides and quinolones. Tetracyclines and macrolides block the protein synthesis by interfering with ribosome translation, while quinolones inhibit the replication of bacterial DNA.
Several antibiotics are commercially available for the removal of mycoplasma: BM-cyclin （Roche） contains a macrolide and a tetracycline, Ciprobay （Bayer, available only with a prescription） and MRA （ICN） are both quinolones. Plasmocin™ is the only antimycoplasma reagent that combines a macrolide and a quinolone. Unlike BM-Cyclin that requires the sequential and cyclic use of 2 antibiotics, Plasmocin™ is ready-to-use and can be added to the culture medium directly. Furthermore, the 2 antibiotics in Plasmocin™ act on separate targets blocking protein synthesis and DNA replication, whereas the 2 antibiotics in BM-Cyclin are both inhibitors of protein synthesis. Therefore, Plasmocin™ is more effective in removing mycoplasma and prevents the appearance of resistant strains. In contrast to other anti-mycoplasma compounds, Plasmocin™ is active on both free mycoplasma as well as intracellular forms. This advantage is conferred by one component of Plasmocin™ which is actively transported into mammalian cells. It ensures that following treatment with Plasmocin™ a cell culture is not reinfected by mycoplasma released from intracellular compartments of infected cells. To date, no consistent and permanent alterations that affect the eukaryotic cells during and after the treatment have been detected[1].

1. Uphoff CC, Drexler HG., 2005. Eradication of mycoplasma contaminations. Methods Mol Biol. 290:25-34.
2. Somasundaram C. et al., 1992. Use of ciprofloxacin and BM-Cyclin in mycoplasma decontamination.In Vitro Cell Dev Biol. 28A（11-12）:708-10
3. Drexler HG. et al., 1994. Treatment of mycoplasma contamination in a large panel of cell cultures. In vitro Cell Dev Biol Anim. 30A（5）:344-7

Recent articles using Plasmocin™

• 2012 – J Virol Methods., Epub ahead of print
  Mycoplasma removal: Simple curative methods for viral supernatants.
  Baronti C, Pastorino B, Charrel R, de Lamballerie X
• 2011 – Mol Pharmacol., 80（6）:1066-75
  Ca2+/calmodulin-dependent kinase （CaMK） signaling via CaMKI and AMP-activated protein kinase contributes to the regulation of WIPI-1 at the onset of autophagy.
  Pfisterer SG, Mauthe M, Codogno P, Proikas-Cezanne T
• 2011 – J Immunol., 186（12）:6822-6829
  Tumor cell programmed death ligand 1-mediated T cell suppression is overcome by coexpression of CD80.
  Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, Britting S, Wolf JB, Ksander BR, Ostrand-Rosenberg S
• 2012 – J. Biol. Chem., 287: 8082 – 8091
  Loss of lysosomal ion channel transient receptor potential channel mucolipin-1 （TRPML1） leads to cathepsin B-dependent apoptosis.
  Colletti GA, Miedel MT, Quinn J, Andharia N, Weisz OA, Kiselyov K
• 2012 – Immunity, 36（3）:464-476
  An NLRP7-containing inflammasome mediates recognition of microbial lipopeptides in human macrophages.
  Khare S, Dorfleutner A, Bryan NB, Yun C, Radian AD, de Almeida L, Rojanasakul Y, Stehlik C

ORDERING

Plasmocin™ prophylactic

• TDS
• MSDS

Plasmocin™ treatment

• TDS
• MSDS

YOU MAY ALSO NEED

MF混合纤维素滤膜AAWP04700优势供应，AAWP04700滤膜现货供应

说明: MF-Millipore 表面滤膜，混合纤维素酯，亲水，0.8 µm，47 mm，白色，光面

商标名: MF-Millipore

数量/包装: 100

滤膜材质: Mixed Cellulose Esters

滤膜商标名: MF-Millipore

折射率: 1.51

水通量，mL/min x cm²: 190

23 °C 时的泡点: ≥1.10 bar

zui高操作温度，°C: 75

滤膜类型: 表面滤膜

滤膜孔径，µm: 0.8

可润湿性: 亲水

滤膜直径，mm: 47

滤膜代码: AAWP

滤膜颜色: 白色

产品名称: MF-Millipore 表面滤膜

滤膜表面: 光面

重量分析溶出物，%: 4

厚度，µm: 180

空气流速，L/min x cm²: 16

孔隙率 %: 82

Swinnex换膜过滤器现货供应，Swinnex换膜过滤器价格 sx0004700 SX0002500 SX0001300

用于对注射器分配的少量液体进行超清洗或除菌。 用导管将 Swinnex 47 mm 过滤器与加压容器或自动注入机相连可过滤较大容量的液体。

应用: 生命科学的研究与开发，制药业及质检，医院制剂

技术指标